Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425646 · ClinicalTrials.gov registry record · Phase 2
Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00425646: Completed Phase 2 study of Lung Cancer, sponsored by University of Washington.
NCT00425646 is a Phase 2 study of Lung Cancer that has completed, run by University of Washington. The registered enrollment target is 50 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00425646, a Phase 2 study of Lung Cancer, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Imatinib mesylate and bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving imatinib mesylate together with bevacizumab as maintenance therapy may stop non-small cell lung cancer from growing or coming back. PURPOSE: This phase II trial is studying how well giving imatinib mesylate together with bevacizumab after first-line chemotherapy and bevacizumab works in treating patients with stage IIIB or stage IV non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG imatinib mesylate
- BIOLOGICAL bevacizumab
Study Locations (1)
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00425646 record still lists
NCT00425646 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which imatinib mesylate is the first listed.
NCT00425646 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00425646 about?
NCT00425646 is a clinical study titled "Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kil...
What is the current status of trial NCT00425646?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2006-11. Estimated completion is 2009-07.
What conditions does trial NCT00425646 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00425646?
The interventions under investigation include: imatinib mesylate (DRUG), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00425646?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00425646 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00425646's enrollment target sits among peer trials
50 264th of 409 higher than 141 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia